Dose Insider / Glossary / SUSTAIN 6

SUSTAIN 6The heart safety trial of Ozempic and what it found

Updated November 20, 2026 · 3 min read · Marso et al., N Engl J Med 2016; OZEMPIC label

SUSTAIN 6 is the cardiovascular trial of semaglutide in people with type 2 diabetes, the trial behind Ozempic's heart indication.

6.6%Semaglutide, first major heart event
First major heart eventSUSTAIN 6, 104 weeks, % of patientsSemaglutide6.6%Placebo8.9%First major heart eventSUSTAIN 6, 104 weeks, % of patientsSemaglutide6.6%Placebo8.9%

Hazard ratio 0.74; non-fatal stroke 1.6% against 2.7%.

On this page

It enrolled 3,297 adults with type 2 diabetes at high cardiovascular risk and gave them weekly semaglutide, 0.5 mg or 1.0 mg, or placebo for 104 weeks on top of usual care. A first heart attack, stroke or cardiovascular death occurred in 6.6% on semaglutide against 8.9% on placebo. It was published in the New England Journal of Medicine in 2016.1

How the trial was run

The trial was built to answer a safety question first: it was designed to show that semaglutide was not worse than placebo for heart events, with a margin of 1.8 for the upper bound of the hazard ratio.1 At the start, 83.0% of participants had established cardiovascular disease, chronic kidney disease or both.1 The Ozempic label describes the trial as enrolling patients with type 2 diabetes and atherosclerotic cardiovascular disease, followed for at least 2 years.2

What it found

Marso et al., 2016.1

The trial met its safety goal and, beyond it, pointed to lower risk. On that basis Ozempic is approved to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.2

The eye finding

SUSTAIN 6 also found something unwelcome. Complications of diabetic eye disease, namely bleeding in the eye, blindness, or conditions needing injections into the eye or laser treatment, were more common on semaglutide, with a hazard ratio of 1.76.1 The Ozempic label gives the numbers from this trial: such complications occurred in 3.0% on semaglutide against 1.8% on placebo. The rise was larger in people who already had diabetic eye disease, 8.2% against 5.2%, than in those who did not, 0.7% against 0.4%. The label also notes that a rapid improvement in blood sugar has been linked to a temporary worsening of diabetic eye disease, and says patients with a history of it should be monitored.2 For people with diabetic eye disease, an eye exam before starting and during treatment is the practical step.

Side effects

Fewer serious adverse events occurred on semaglutide than on placebo, but more people stopped the drug because of adverse events, mainly in the stomach and gut.1 In the Ozempic label's placebo-controlled trials, nausea was reported by 15.8% on 0.5 mg and 20.3% on 1 mg, against 6.1% on placebo.2 Our page on Ozempic side effects gives the full rates.

Among the heart trials

SUSTAIN 6 sits in a series of heart trials of GLP-1 medicines that used the same three-part outcome. LEADER, for liraglutide, found 13.0% against 14.9%; REWIND, for dulaglutide, 12.0% against 13.4%; and SELECT, for semaglutide 2.4 mg in people without diabetes, 6.5% against 8.0%.3,4,5 The trials differ in people, doses and length, so their percentages are not directly comparable.

Limits

The trial was relatively small for a heart trial, with 3,297 people, and lasted two years. Its design aimed to rule out harm rather than prove benefit, so the benefit seen was not its formal test. It was funded by Novo Nordisk.1

Sources

  1. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med 2016;375:1834-1844. Funded by Novo Nordisk; NCT01720446. doi:10.1056/NEJMoa1607141
  2. OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; sections 1, 5, 6.1 and 14.2. accessdata.fda.gov
  3. VICTOZA (liraglutide) injection prescribing information. Novo Nordisk; DailyMed, version published November 17, 2025; section 14. dailymed.nlm.nih.gov
  4. TRULICITY (dulaglutide) injection prescribing information. Eli Lilly and Company; DailyMed, version published August 10, 2026; section 14.5. dailymed.nlm.nih.gov
  5. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med 2023;389:2221-2232. doi:10.1056/NEJMoa2307563

Related analyses

Log your doses, blood sugar and eye checkups in one place.

Open Dose Insider